Inflammatory cytokines and NT-proCNP in Parkinson's disease patients

Cytokine

Volumn 60, Issue 3, 2012, Pages 762-766

  Koziorowski, Dariusz ^a   Tomasiuk, Ryszard ^b   Szlufik, Stanisław ^a   Friedman, Andrzej ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b Brodnowski Hospital Warsaw   (Poland)

Author keywords

Cytokines; Inflammatory factors; NT proCNP; Parkinson's disease; TNF

Indexed keywords

AMINO TERMINAL PRO NATRIURETIC PEPTIDE TYPE C; CYTOKINE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; NATRIURETIC FACTOR; PROTEIN PRECURSOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INFLAMMATION; LABORATORY DEVICE; MAJOR CLINICAL STUDY; MALE; MOLECULAR PATHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS;

CYTOKINES; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, C-TYPE; PARKINSON DISEASE;

PARKINSONIA;

EID: 84867985183     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2012.07.030     Document Type: Article

References (35)

1. Teismann P., Tiku K., Cohen O., et al. Pathogenic role of glial cells in Parkinson's disease. Mov Disord 2003, 18:121-129.
2. Chen H., Zhang S.M., Herman M.A., et al. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003, 60:1059-1064.
3. Goralski K.B., Renton K.W. Brain inflammation enhances 1-methyl-4-phenyl-1,2,3,6-tetrahydropiridinium (MPTP) evoked neurotoxicity in rats. Toxicol Appl Pharmacol 2004, 196:381-389.
4. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett 1994, 165:208-210.
5. Nagatsu T., Sawada M. Inflammatory process in Parkinson's disease: role for cytokines. Curr Pharm Des 2005, 11:999-1016.
6. Mogi M., Harada M., Narabayashi H., Inagaki H., Minami M., Nagatsu T. Interleukin (IL)-1beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease. Neurosci Lett 1996, 211:13-16.
7. Brodacki B., Staszewski J., Toczylowska B., et al. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFalpha, and INFgamma concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neurosci Lett 2008, 441:158-162.
8. Rentzos M., Nikolaou C., Andreadou E., et al. Circulating interleukin-10 and interleukin-12 in Parkinson's disease. Acta Neurol Scand 2009, 119:332-337.
9. Reale M., Iarlori C., Thomas A., et al. Peripheral cytokines profile in Parkinson's disease. Brain Behav Immun 2009, 23:55-63.
10. Qin L., Wu X., Block M.L., et al. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55:453-462.
11. Hunot S., Dugas N., Faucheux B., et al. Fcepsilon-RII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells. J Neurosci 1999, 19:3440-3447.
12. Frank-Cannon T.C., Tran T., Ruhn K.A., et al. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci 2008, 28:10825-10834.
13. Suga S., Nakao K., Itoh H., et al. Endothelial production of C-type natriuretic peptide and its marked augmentation by transforming growth factor-beta. Possible existence of 'vascular natriuretic peptide system. J Clin Incest 1992, 90:1145-1149.
14. Wu C., Wu F., Pan J., Morser J., Wu Q. Furinmediated processing of pro-C-type natriuretic peptide. J Biol Chem 2003, 278:25847-25852.
15. Stingo A.J., Clavell A.L., Heublein D.M., Wei C.M., Pittelkow M.R., Burnett J.C. Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. Am J Physiol 1992, 263:H1318-H1321.
16. Koch A., Voigt S., Sanson E., et al. Prognostic value of circulating amino-terminal pro-C-type natriuretic peptide in critically ill patients. Crit Care 2011, 15:R45.
17. Bahrami S., Pelinka L., Khadem A., et al. Circulating NTproCNP predicts sepsis in multiple-traumatized patients without traumatic brain injury. Crit Care Med 2010, 38:161-166.
18. Suga S., Itoh H., Komatsu Y., et al. Cytokine induced C-type natriuretic peptide (CNP) secretion from vascular endothelial cells - evidence for CNP as a novel autocrine/paracrine regulator from endothelial cells. Endocrinology 1993, 133:3038-3041.
19. Boka G., Anglade P., Wallach D., Javoy-Agid F., Agid Y., Hirsch E.C. Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett 1994, 172:151-154.
20. Dobbs R.J., Charlett A., Purkiss A.G., Dobbs S.M., Weller C., Peterson D.W. Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism. Acta Neurol Scand 1999, 100:34-41.
21. Katsarou Z., Bostantjopoulou S., Hatzizisi O., Giza E., Soler-Cardona A., Kyriazis G. Immune factors or depression? Fatigue correlates in Parkinson's disease. Rev Neurol 2007, 45:725-728.
22. Scalzo P., Kümmer A., Cardoso F., Teixeira A.L. Increased serum levels of soluble tumor necrosis factor-alpha receptor-1 in patients with Parkinson's disease. J Neuroimmunol 2009, 216:122-125.
23. Arimoto T., Choi D.Y., Lu X., et al. Interleukin-10 protects against inflammation-mediated degeneration of dopaminergic neurons in substantia nigra. Neurobiol Aging 2006, 28:894-906.
24. Szczepanic A.M., Funes S., Petko W., Ringheim G.E. IL-4, IL-10 and IL-13 modulate Abeta(1-42)- induced cytokine and chemokine production in primary murine microglia and a human monocyte cell line. J Neuroimmunol 2001, 113:49-62.
25. Szczepanic A.M., Ringheim G.E. IL-10 and glucocorticoids inhibit Abeta(1-42)-and lipopolysaccharide-induced proinflammatory cytokine and chemokine induction in the central nervous system. J Alzheimers Dis 2003, 5:105-117.
26. Combarros O., Sanchez-Juan P., Riancho J.A., et al. Aromatase and interleukin-10 genetic variants modulate Alzheimer's disease risk. J Neural Trans 2008, 115:863-867.
27. Jifen L., Bruno G., Guang-Xian Zhang, et al. Differential expression and regulation of IL-23 and IL-12 subunits and receptors in adult mouse microglia. J Neurol Sci 2003, 215:95-103.
28. Chen H., O'Reilly E.J., Schwarzschild M.A., Ascherio A. Peripheral inflammatory biomarkers and risk of Parkinson's disease. Am J Epidemiol 2008, 167:90-95.
29. Dufek M., Hamanova M., Lokaj J., et al. Serum inflammatory biomarkers in Parkinson's disease. Parkinsonism Relat Disord 2009, 15:318-320.
30. Scalzo P., Kümmer A., Cardoso F., Teixeira A.L. Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance. Neurosci Lett 2010, 468:56-58.
31. Stypula G., Kunert-Radek J., Stepien H., Zylinska K., Pawlikowski M. Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with Parkinson's disease. Neuroimmunomodulation 1996, 3:131-134.
32. Hofmann K.W., Schuh A.F., Saute J., et al. Interleukin-6 serum levels in patients with Parkinson's disease. Neurochem Res 2009, 34:1401-1404.
33. Bessler H., Djaldetti R., Salman H., Bergman M., Djaldetti M. IL-1beta, IL-2, IL-6 and TNF-a production by peripheral blood mononuclear cells from patients with Parkinson's disease. Biomed Pharmacother 1999, 53:141-145.
34. Hasegawa Y., Inagaki T., Sawada M., Suzumura A. Impaired cytokine production by peripheral blood mononuclear cells and monocytes/macrophages in Parkinson's disease. Acta Neurol Scand 2000, 101:159-164.
35. Selikhova M.V., Kushlinskii N.E., Lyubimova N.V., Gusev E.I. Impaired production of plasma interleukin-6 in patients with Parkinson's disease. Bull Exp Biol Med 2002, 133:81-83.